IL-17A Enhances Retinal Neovascularization

Taylor, Brooklyn E.; Lee, Chieh A.; Zapadka, Thomas E.; Zhou, Amy Y.; Barber, Katherine G.; Taylor, Zakary R. R.; Howell, Scott J.; Taylor, Patricia R.

doi:10.3390/ijms24021747

Cited by 5 publications

(3 citation statements)

References 23 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have found that diabetes-mediated IL-17A enhances VEGF production in the retina, Muller glial cells, and retinal endothelial cells, and that IL-17A induces retinal endothelial cell proliferation and can enhance VEGF-dependent vascular neovascularization. Finally, a model of oxygen-induced retinopathy showed that IL-17A promotes retinal neovascularization ( 23 ). The current literature is more scattered in showing IL-17A as a possible cause of DR pathogenesis, but none of the more scientific studies have established the inevitability of their relationship.…”

Section: Discussionmentioning

confidence: 99%

Meta-analysis of the relationship between ocular and peripheral serum IL-17A and diabetic retinopathy

Li,

Qin,

Qin

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

PurposeA systematic evaluation and Meta-analysis were performed to determine the relationship between IL-17A levels in ocular aqueous and peripheral venous serum samples and diabetic retinopathy (DR).MethodsPubMed, Embase, Web of Science, and CNKI databases were searched from the time of library construction to 2023-09-20.The results were combined using a random-effects model, sensitivity analyses were performed to determine whether the arithmetic was stable and reliable, and subgroup analyses were used to look for possible sources of heterogeneity.ResultsA total of 7 case-control studies were included. The level of IL-17A was higher in the Nonproliferative DR(NPDR) group than in the Non-DR(NDR) group [SMD=2.07,95%CI(0.45,3.68),P=0.01], and the level of IL-17A in the proliferating DR(PDR) group was higher than that of the NDR group [SMD=4.66,95%CI(1.23,8.08),P<0.00001]. IL-17A levels in peripheral serum and atrial fluid were significantly higher in NPDR and PDR patients than in non-DR patients in subgroup analyses, and detection of peripheral serum IL-17A concentrations could help to assess the risk of progression from NPDR to PDR. Sensitivity analyses suggested that the results of the random-effects arithmetic were stable and reliable. Subgroup analyses based on assay method and sample source showed that the choice of these factors would largely influence the relationship between IL-17A levels and DR.ConclusionElevated peripheral serum and ocular aqueous humor IL-17A levels in diabetic patients are associated with the risk of DR, IL-17A may serve as a potential predictor or therapeutic target for DR, and IL-17A may be an important predictor of inflammation for the progression of NPDR to PDR.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42024532900.

show abstract

Section: Discussionmentioning

confidence: 99%

Meta-analysis of the relationship between ocular and peripheral serum IL-17A and diabetic retinopathy

Li,

Qin,

Qin

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…However, IL-17 also contributes to an inflammatory environment that can adversely affect endothelial cell function and angiogenesis. For instance, IL-17 has been shown to increase the production of pro-inflammatory cytokines and chemokines, which can lead to endothelial dysfunction and impaired angiogenic response [ 83 , 84 ].…”

Section: Targeting Il-17 Pathways For Enhanced Healing In Chronic Wou...mentioning

confidence: 99%

IL-17 in wound repair: bridging acute and chronic responses

Mu,

Gu,

Tang

et al. 2024

Cell Commun Signal

View full text Add to dashboard Cite

Chronic wounds, resulting from persistent inflammation, can trigger a cascade of detrimental effects including exacerbating inflammatory cytokines, compromised blood circulation at the wound site, elevation of white blood cell count, increased reactive oxygen species, and the potential risk of bacterial infection. The interleukin-17 (IL-17) signaling pathway, which plays a crucial role in regulating immune responses, has been identified as a promising target for treating inflammatory skin diseases. This review aims to delve deeper into the potential pathological role and molecular mechanisms of the IL-17 family and its pathways in wound repair. The intricate interactions between IL-17 and other cytokines will be discussed in detail, along with the activation of various signaling pathways, to provide a comprehensive understanding of IL-17’s involvement in chronic wound inflammation and repair.

show abstract

“…In the peripheral blood mononuclear cells of patients with proliferative diabetic retinopathy (PDR), IL-35 lowers IL-17 levels and inhibits Th17 cell differentiation, offering protection against PDR ( 167 ). The proinflammatory cytokine IL-17 is elevated in the plasma and vitreous of diabetic patients, and the worsening of DR is linked to increased retinal IL-17A expression through Act1 signaling, which leads to Müller cell dysfunction ( 168 , 169 ), and promotes retinal neovascularization ( 170 ). In PDR, vitreous IL-17A levels are associated with IL-10, IL-22, and TNFα levels in the aqueous humor and vitreous ( 171 ).…”

Section: Retinal Inflammation In Diabetic Retinopathymentioning

confidence: 99%

Cell and molecular targeted therapies for diabetic retinopathy

Reddy,

Devi,

Seetharaman

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

Diabetic retinopathy (DR) stands as a prevalent complication in the eye resulting from diabetes mellitus, predominantly associated with high blood sugar levels and hypertension as individuals age. DR is a severe microvascular complication of both type I and type II diabetes mellitus and the leading cause of vision impairment. The critical approach to combatting and halting the advancement of DR lies in effectively managing blood glucose and blood pressure levels in diabetic patients; however, this is seldom achieved. Both human and animal studies have revealed the intricate nature of this condition involving various cell types and molecules. Aside from photocoagulation, the sole therapy targeting VEGF molecules in the retina to prevent abnormal blood vessel growth is intravitreal anti-VEGF therapy. However, a substantial portion of cases, approximately 30–40%, do not respond to this treatment. This review explores distinctive pathophysiological phenomena of DR and identifiable cell types and molecules that could be targeted to mitigate the chronic changes occurring in the retina due to diabetes mellitus. Addressing the significant research gap in this domain is imperative to broaden the treatment options available for managing DR effectively.

show abstract

IL-17A Enhances Retinal Neovascularization

Cited by 5 publications

References 23 publications

Meta-analysis of the relationship between ocular and peripheral serum IL-17A and diabetic retinopathy

Meta-analysis of the relationship between ocular and peripheral serum IL-17A and diabetic retinopathy

IL-17 in wound repair: bridging acute and chronic responses

Cell and molecular targeted therapies for diabetic retinopathy

Contact Info

Product

Resources

About